Clinical RoundupFree Phase III CheckMate-743 study of Opdivo and Yervoy meets primary OS endpoint in mesothelioma April 24, 2020Vol.46 No.17
Clinical RoundupFree Phase III CheckMate -9ER meets primary PFS endpoint in RCC April 24, 2020Vol.46 No.17
Clinical RoundupFree New targeted agent produces responses in trial with patients with uterine serous carcinoma April 24, 2020Vol.46 No.17
Clinical RoundupFree RVD Therapy shows substantial benefit in large myeloma study April 24, 2020Vol.46 No.17
Clinical RoundupFree Cue Biopharma and Merck to evaluate CUE-101 + Keytruda in head and neck indication April 24, 2020Vol.46 No.17
FreeIn Brief Poynter, Harki appointed to leadership team at Masonic Cancer Center April 24, 2020Vol.46 No.17
FreeIn Brief American Heart Association grants $17 million for studies on health impact of e-cigarettes and nicotine on youth April 24, 2020Vol.46 No.17
